Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer

• Published in: PloS one 2014-02, Vol.9 (2), p.e87780
• Main Authors: Zhu, Wangyu, He, Jianying, Chen, Dongdong, Zhang, Bingjie, Xu, Liyun, Ma, Haijie, Liu, Xiaoguang, Zhang, Yongkui, Le, Hanbo
• Format: Article
• Language: English
• Subjects: Aberration; Adult; Aged; Analysis; Area Under Curve; Bioindicators; Biology; Biomarkers; Biomarkers, Tumor - metabolism; Cancer; Cancer therapies; Carcinogenesis; Carcinogens; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - metabolism; Case-Control Studies; Cell cycle; Cohort Studies; Development and progression; Embryos; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Laboratories; Lung cancer; Lung diseases; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Male; Medical diagnosis; Medical prognosis; Medicine; Metastasis; MicroRNA; MicroRNAs; MicroRNAs - genetics; MicroRNAs - metabolism; Middle Aged; miRNA; Non-small cell lung cancer; Non-small cell lung carcinoma; Patients; Polymerase chain reaction; Prognosis; Prostate; ROC Curve; Serum levels; Studies; Surgery; Thoracic surgery; Tissues; Tumors
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0087780

Altered expression of miRNA expression contributes to human carcinogenesis. This study was designed to detect aberrant miRNA expressions as a potential biomarker for early detection and prognosis prediction of non-small cell lung cancer (NSCLC). miRNA array was used to profile differentially expressed miRNAs and Taqman-based quantitative RT-PCR assays were used to analyze levels of miR-29c, miR-93, and miR-429 expression in NSCLC tissue samples, corresponding normal tissue samples, and serum samples from 70 NSCLC patients as well as in serum samples from 48 healthy controls. Levels of miR-29c and miR-93 expression were upregulated in NSCLC tissues, while serum levels of miR-29c were also upregulated, but levels of serum miR-429 were decreased in NSCLC. Moreover, the levels of miR-429 expression in NSCLC tissues were associated with those in serum samples. Receiver operating characteristic (ROC) curve analysis showed that at the optimal cut-off point, the areas under the ROC curve for serum levels of miR-29c and miR-429 were 0.723 and 0.727, respectively, levels which are higher than that of carcinoma embryonic antigen (0.534) in diagnosis of stage I NSCLC. In addition, serum levels of miR-429 were associated with poor overall survival of NSCLC patients. Both univariate and multivariate analyses showed that serum miR-429 level was an independent prognostic predictor for NSCLC. The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel, non-invasive biomarker for early stage NSCLC.